Patent Application

Attorney Docket No.: PC23060A

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: BUZON, ET AL.

APPLICATION NO.: NOT YET ASSIGNED

:Examiner: NOT ASSIGNED

FILING DATE:

**HEREWITH** 

TRIAZOLO-PYRIDINES

: Group Art Unit: NOT ASSIGNED

TITLE:

ķ

NOVEL PROCESSES AND: INTERMEDIATES FOR PREPARING

Mail Stop PATENT APPLICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

North 1

GARTH BUTTERFIELL Attorney for Applicants

Reg. No. 36,997

Pfizer Inc

Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 573-1229

USERS\DOCS\LA21952\LPGXB\4H\0011.DOC/209736 INFORMATION DISCLOSURE STATEMENT, 05/03, (1/1)

EXAMINER INITIAL	seral sh	neets if i		ary) 	FIL	PLICANT		ZON, ET	AL.	1				
	5	7	DOC			ING DA	TE HER							
	5	7	DOC			FILING DATE HEREWITH				GROUP NOT ASSIGNE				ED
	5	7	DOC			PATENT	DOCU	,			<del>,</del>	T		
	5	7		CUMENT NUM	IBER	r	<del></del>	DATE	N	NAME	CLASS	SUBCLASS	FILING IF APPROF	=
		7	1	6	9	5	5	2/10/98	ADAMS, ET AL		514	235.8		
	_	7	1	6	9	7	2	2/10/98	ADAM	S, ET AL.	514	341		
	<del></del>	7	1	7	1	0	0	2/10/98	SELNICK, ET AL.  ADAMS, ET AL.  LEE, ET AL.  ADAMS, ET AL.		546	194		
	5	7	5	6	4	9	9	5/26/98			514	235.8		
	5	7	7	7	0_	9	7	7/7/98			536	24.31		
	6	2	8	8	0	6	2	9/11/01			514	236.8		
				F(	OREIG	N PATE	NT DO	CUMENTS	3				<del></del>	
	DOCUMENT NUMBER								COUNTRY		CLASS	SUBCLASS	TRANSL YES	ATION NO
	9	9	0	1	4	4	_9	1/14/99	РСТ		C07D	401/04	100	INC.
	9	9	6	1	4	4	0	12/2/99	PCT		C07D	403/14		
	0	0_	0	6	5_	6	3	2/10/00	F	РСТ	C07D	401/04		L
	0	0_	3	1	_ 0	6	5	6/2/00	PCT PCT PCT		C07D	401/04	·	L
	0	0	3	5	9	1	1	6/22/00			C07D	405/14		<u></u>
	0	0	4	0	2	4	3	7/13/00			A61K	31/444		<u> </u>
	0	0	4	1	6	9	8	7/20/00	F	PCT	A61K	31/535		<u> </u>
	0	0	6	3	2	0	4	10/26/00	F	СТ	C07D	413/00		<u> </u>
	0	2	7	2	5	7	6	9/19/02	F	РСТ	C07D	403/14		<u> </u>
	0	2	7	2	5	7	9	9/19/02	F	РСТ	C07D	471/04		<u> </u>
	_1	2	4	7	_ 8	11	0	10/9/02		EP	C07D	403/04		<u></u>
		OTHE	R DOCL	JMENTS	3 (Inclu	ıding Au	thor, Titl	e, Date, F	<sup>p</sup> ertinent	Pages, Et	tc.)			
	The Jo	ournal of	Biological	Chemistr	y, Vol. 2	71, No. 40	, pp. 2431	3-24316 (19	96);					
	Bioorg	anic & M	edicinal C	hemistry	Letters,	10, pp. 204	<del>17-2050 (2</del>	2000); and						
	Bioorg	anic & M	edicinal C	Chemistry	Letters,	11, pp. 9-1		<del></del>	<del></del>					
EXAMINER							DATE C	ONSIDERE	D 					
EXAMINER: Initial if referential in the second terms of the second			ther or not d	itation is in co	nformance	with MPEP 6	09; Draw line	through citation	if not in confo	ormance and not o	considered.	Include copy of	this form	n

1

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE